EGR2 and thyroid gland carcinoma: Furthermore, the levels of E-cadherin and MAPK in tumor tissues from the miR-17-5p inhibition group were decreased in comparison with the control group (Figure 5(d)), indicating miR-17-5p promote thyroid cancer tumorigenicity by suppressing EGR2.